ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 15, 2018 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics to treat serious diseases, is hosting its 2nd R&D update on "Building Tomorrow's Breakthroughs."
When:
Thursday, December 6, 2018
Check-In & Lunch 11:30am - 12:00pm ET
Presentations and Q&A 12:00pm - 2:30pm ET
Where:
The Yale Club
50 Vanderbilt Avenue
New York, NY 10017
Discussion topics will include:
- Development strategy for MP0250 in multiple myeloma and
update on clinical trials in NSCLC and multiple myeloma - Advancement of immuno-oncology pipeline
- Research strategy and new research programs of the company
- Latest clinical data on Allergan-licensed abicipar
A detailed agenda, including speakers and presentation titles as they are confirmed, can be found on the respective Molecular Partners' R&D Day 2018 website ahead of the event.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals. Space is limited: Please RSVP by emailing Susan A. Noonan at susan@sanoonan.com.
Webcast information:
For those who are unable to attend in person, a live webcast and replay will be accessible on the company's website, along with the accompanying presentation slides.
About the DARPin® Difference
DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates can engage more than 5 targets at once, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.
With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology, and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid tumors and hematological tumors. MP0274, the second-most advanced DARPin® drug candidate owned by Molecular Partners, has broad anti-HER activity; it inhibits HER1, HER2 and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis. MP0274 is currently in phase 1. Molecular Partners is also advancing a growing preclinical pipeline that features several immuno-oncological development programs. DARPin® is a registered trademark owned by Molecular Partners AG.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapeutics. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.
For more information regarding Molecular Partners AG, go to www.molecularpartners.com.
For further details, please contact:
Dr. Patrick Amstutz, CEOpatrick.amstutz@molecularpartners.com
Tel: +41 (0) 44 755 77 00
Thomas Schneckenburger, IR Europe
thomas.schneckenburger@molecularpartners.com
Tel: +41 (0) 44 755 5728
Susan A. Noonan, IR USA
susan@sanoonan.com
Tel: +1 212 966 3650
Lisa Raffensperger, International Media
lisa@tenbridgecommunications.com
Tel: +1 617-903-8783
SOURCE: Molecular Partners AG
View source version on accesswire.com:
https://www.accesswire.com/525301/Molecular-Partners-Invites-Investors-to-Participate-in-its-2018-RD-Day
